Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients between the ages of 18 to 75 years, inclusive.~2. Patients who have met DSM-5 criteria for bipolar I or II disorder.~3. Patients who are judged to be clinically agitated at Screening and Baseline with a total score of ≥ 14 on the 5 items (poor impulse control, tension, hostility, uncooperativeness, and excitement) comprising the PANSS Excited Component (PEC).~4. Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline.~5. Patients who read, understand and provide written informed consent.~6. Patients who are in good general health prior to study participation as determined by a detailed medical history, physical examination, 12-lead ECG with rhythm strip, blood chemistry profile, hematology, urinalysis, and in the opinion of the Principal Investigator.~7. Participants who agree to use a medically acceptable and effective birth control method~Exclusion Criteria:~1. Patients with agitation caused by acute intoxication, including positive identification of alcohol by breathalyzer or drugs of abuse (with the exception of THC) during urine screening.~2. Use of benzodiazepines or other hypnotics or oral or short-acting intramuscular antipsychotic drugs in the 4 hours before study treatment.~3. Treatment with alpha-1 noradrenergic blockers (terazosin, doxazosin, tamsulosin, alfuzosin, or prazosin) or other prohibited medications.~4. Patients who are judged to be at significant risk of suicide.~5. Female patients who have a positive pregnancy test at screening or are breastfeeding.~6. Patients who have hydrocephalus, seizure disorder, or history of significant head trauma, stroke, transient ischemic attack, subarachnoid bleeding, brain tumor, encephalopathy, meningitis, Parkinson's disease or focal neurological findings.~7. History of syncope or other syncopal attacks, current evidence of hypovolemia, orthostatic hypotension.~8. Patients with laboratory or ECG abnormalities considered clinically significant by the investigator.~9. Patients with serious or unstable medical illnesses.~10. Patients who have received an investigational drug within 30 days prior to the current agitation episode.~11. Patients who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving DEX.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 120 Micrograms (Type: EXPERIMENTAL): Sublingual film containing 120 Micrograms Dexmedetomidine
- 180 Micrograms (Type: EXPERIMENTAL): Sublingual film containing 180 Micrograms Dexmedetomidine
- Placebo (Type: PLACEBO_COMPARATOR): Sublingual placebo film

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete